Indication
Extranodal NK/T Cell Lymphoma
3 clinical trials
4 products
Product
IBI318Clinical trial
Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type), a Multicenter, Open-label Phase Ib/II TrialStatus: Terminated, Estimated PCD: 2023-02-28
Clinical trial
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasStatus: Recruiting, Estimated PCD: 2024-12-01
Product
DR-01Clinical trial
The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell LymphomaStatus: Not yet recruiting, Estimated PCD: 2026-12-31
Product
ChidamideProduct
DDGP